Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Florida
M.D. Anderson Cancer Center
British Columbia Cancer Agency
Centre Antoine Lacassagne
OHSU Knight Cancer Institute
Oncovir, Inc.
Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)